HARP News and Press, Harpoon Therapeutics Inc. From 10/23/23

2023-10-23 05:32:56 ET Stock futures fell slightly in premarket trading on Monday as U.S. Treasury yields remained near multiyear highs amid investor concerns about rising interest rates ahead of big tech earnings reports. For further details see: Biggest stock movers today: Crypto-...

Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete responses 32% (6/19) confirmed response rate in patients with small cell lung cancer (SCLC), including one confirmed complete response ...

Harpoon Therapeutics, Inc. (NASDAQ: HARP) is one of today's top gainers. The company's shares are currently up 18.5% on the day to $6.34. Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of...

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a live webcast at 8:00 a.m. ET / 2:00 p.m. CEST on Monday, October 23, 2023 to ...

2023-10-13 13:36:57 ET Gainers: Sigma Additive Solutions ( SASI ) +138% . P & F Industries ( PFIN ) +87% . Bio-Path Holdings ( BPTH ) +61% . MicroAlgo ( MLGO ) +31% . Comtech Telecommunications Corp. ( CMTL ) +29% . PSQ H...

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will present interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328...

Target dose of 12 mg demonstrates robust early activity and manageable tolerability profile: – 63% ORR, 16% cytokine release syndrome (CRS), No ICANS – Phase 1 data set, including recommended Phase 2 dose(s) (RP2D), to be presented by the end of 2023 SOUTH SAN FR...

SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced dosing of the first patients with small cell lung cancer (SCLC) in an ongoing Phase 1/2 trial of HP...

2023-09-14 13:39:25 ET Gainers: TradeUP Acquisition Corp. ( UPTD ) +62% . PFSweb ( PFSW ) +48% . Bruush Oral Care ( BRSH ) +33% . Nikola Corporation ( NKLA ) +25% . ENDRA Life Sciences ( NDRA ) +24% . First Wave BioPharma ( ...

2023-09-13 17:22:37 ET More on Harpoon Therapeutics Seeking Alpha’s Quant Rating on Harpoon Therapeutics Historical earnings data for Harpoon Therapeutics Financial information for Harpoon Therapeutics For further details see: Harpoon up even as Ab...